Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL49814

CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.O=P([O-])([O-])[O-]

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A known ✓ P35348 1/20 0.45
KCNH2 known ✓ Q12809 1/20 0.45
SLC22A1 O15245 4/20 0.71
SLC22A2 O15244 1/20 0.61
ALDH1A1 P00352 1/20 0.55
TP53 P04637 1/20 0.55
CYP3A4 P08684 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
ALOX12 P18054 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HIF1A Q16665 1/20 0.55
HSD17B10 Q99714 1/20 0.55
DNM1 Q05193 5/20 0.50
LMNA P02545 1/20 0.45
ESR1 P03372 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CDC25A P30304 1/20 0.45
AGTR1 P30556 1/20 0.45
AKT1 P31749 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL19834900 1.00 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3795562 0.97 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL29164920 0.97 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL703752 0.97 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28973535 0.97 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28547695 0.97 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3141779 0.97 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL31067882 0.97 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL7641913 0.95 SLC22A1 (0.63) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL7626792 0.95 SLC22A1 (0.63) SLC22A1SLC22A2ALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079810-A Aromatic diamine and polyimide containing amido, preparation method and application thereof 2026-05-26 CN claimed
EP-4690281-A1 COMPOSITION FOR TIN HARD MASK REMOVAL WHILE COMPATIBLE WITH TUNGSTEN Versum Materials US, LLC (US) 2026-02-11 EP claimed
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES ENTEGRIS INC (US) 2026-01-15 US claimed
US-20250388596-A1 PROCESS FOR THE EXTRACTION AND PURIFICATION OF TETRODOTOXIN WEX PHARMACEUTICALS INC (CA) 2025-12-25 US claimed
US-20250382711-A1 METHOD OF PREPARING 2-HYDROXYADPIC ACID AND ADIPIC ACID NATIONAL CHENG KUNG UNIVERSITY (TW) 2025-12-18 US claimed
US-20250362278-A1 MASS SPECTROMETRY OF MRNA MODERNATX, INC. (US) 2025-11-27 US claimed
EP-4565694-A1 EXTRACTION-LESS REVERSE PHASE (RP) CHROMATOGRAPHY FOR MRNA PURITY ASSESSMENT ModernaTX, Inc. (US) 2025-06-11 EP claimed
WO-2025111479-A1 FLUOROGENIC SUBSTRATES AND METHODS OF USE ABBOTT LABORATORIES (US) 2025-05-30 WO claimed
WO-2025104679-A1 PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-05-22 WO claimed
EP-4551585-A1 PROCESS FOR THE EXTRACTION AND PURIFICATION OF TETRODOTOXIN Wex Pharmaceuticals Inc. (CA) 2025-05-14 EP claimed
EP-2095188-A1 HARDMASK COMPOSITION FOR PROCESSING RESIST UNDERLAYER FILM, PROCESS FOR PRODUCING SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE USING THE HARDMASK COMPOSITION, AND SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE PRODUCED BY THE PROCESS Cheil Industries Inc. (KR) 2009-09-02 EP claimed
WO-2009088177-A2 SILICON-BASED HARDMASK COMPOSITION (SI-SOH; SI-BASED SPIN-ON HARDMASK) AND PROCESS OF PRODUCING SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE USING THE SAME CHEIL INDUSTRIES INC. (KR) 2009-07-16 WO claimed
WO-2009016269-A1 WATER-SOLUBLE ETHYLIDENE PHOSPHATE PRODRUG OF PROPOFOL OY FENNOPHARMA LTD (FI) 2009-02-05 WO claimed
WO-2008063016-A1 HARDMASK COMPOSITION FOR PROCESSING RESIST UNDERLAYER FILM, PROCESS FOR PRODUCING SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE USING THE HARDMASK COMPOSITION, AND SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE PRODUCED BY THE PROCESS CHEIL INDUSTRIES INC. (KR) 2008-05-29 WO claimed
US-20080118875-A1 Hardmask composition and associated methods CHEIL INDUSTRIES, INC. (KR) 2008-05-22 US claimed
US-7355059-B2 Preparation of sulfide chain-bearing organosilicon compounds SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-04-08 US claimed
US-20050196789-A1 Preparation of biologically derived fluids for biomarker determination by mass spectrometry APPLERA CORPORATION (US) 2005-09-08 US claimed
US-6773822-B2 ANTIFUNGAL AGENT MAY BE PRESENT IN THE GYPSUM CORE AND/OR ON ONE OR BOTH OF THE PAPER FACINGS, AND MAY BE ENCAPSULATED IN A MATERIAL THAT RELEASES THE ANTIFUNGAL AGENT OVER TIME AND/OR UPON EXPOSURE TO MOISTURE. TEMPLE-INLAND FOREST PRODUCTS CORPORATION 2004-08-10 US claimed
EP-0367447-A1 Human epithelial transforming growth factor SMITHKLINE BEECHAM CORPORATION (US) 1990-05-09 EP claimed
US-4522729-A CXONTACTING IMPORITIES WITH TETRAALKYLAMMONIUM SALT PHILLIPS PETROLEUM COMPANY (US) 1985-06-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES TET2, ASIC1, PIEZO1 ADRA1A 2285/4885KCNH2 411/4885SLC22A1 2747/4885
US-20250388596-A1 PROCESS FOR THE EXTRACTION AND PURIFICATION OF TETRODOTOXIN TRPA1, CACNA1D, SCN2A ADRA1A 398/4885KCNH2 58/4885SLC22A1 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.